Real World Study of End-stage Liver Disease in China

Launched by HUASHAN HOSPITAL · Jul 29, 2019

Keywords

ClinConnect Summary

This clinical trial, called the "Real World Study of End-stage Liver Disease in China," is looking to understand how end-stage liver disease is currently diagnosed and treated in China. End-stage liver disease happens when the liver is severely damaged and can no longer perform its essential functions for the body. The study aims to explore the problems and complications that come with liver cirrhosis, a common cause of end-stage liver disease, and to improve the way patients are diagnosed and treated.

To participate in this study, individuals should be between 65 and 74 years old and must have a diagnosis of liver-related conditions, such as acute liver failure or cirrhosis. Participants will need to give their consent to join the study. However, individuals with certain serious health issues, like severe mental illnesses or other major organ diseases, will not be eligible. If you qualify and decide to participate, you can expect to help researchers gather important information that could lead to better care for people with end-stage liver disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Informed consent of patients.
• • 2. Diagnosis of any of the following diseases: acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure and hepatocellular carcinoma (stage III-IV)
• Exclusion Criteria:
• • 1. HIV antibody positive and AIDS patients
• • 2. Serious psychiatric history, especially depression. Severe mental illness is defined as major depression or psychosis, suicide attempts, hospitalization due to mental illness or a period of disability due to mental illness.
• • 3. Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.
• • 4. Patients with other malignant tumors (excluding those cured).
• • 5. Pregnant, lactating women or women of childbearing age who are ready to conceive.